[Introduction to the topic: Off-label use of bevacizumab in the treatment of neovascular age-related macular degeneration].
Bartz-Schmidt
K U
KU
Augenklinik, Eberhard-Karls-Universität, Schleichstrasse 12, 72076 Tübingen. u.bartz-schmidt@uni-tuebingen.de
Holz
F G
FG
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D017277:Drug Approval; D004348:Drug Labeling; D006801:Humans; D008268:Macular Degeneration / Q000150:complications / Q000188:drug therapy*; D010818:Practice Patterns, Physicians'; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab